Dianthus Therapeutics, Inc. $DNTH Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. cut its Dianthus Therapeutics stake by 11.2% in the third quarter, selling 22,923 shares and ending the period with 181,291 shares worth about $16.0 million. Other institutional investors, including Assenagon and Pictet, increased their holdings.
• Company insiders sold 45,902 shares worth approximately $4.8 million over the past three months. Insiders own 3.02% of the stock.
• Analysts’ consensus rating is Buy, with an average price target of $128.77. Dianthus reported a quarterly loss of $0.81 per share, better than the $0.94 loss analysts expected, and revenue of $1.21 million versus estimates of $0.46 million.

Candriam S.C.A. reduced its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 11.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 181,291 shares of the company's stock after selling 22,923 shares during the quarter. Candriam S.C.A. owned about 0.33% of Dianthus Therapeutics worth $16,021,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Dianthus Therapeutics in the second quarter valued at approximately $401,990,000. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 24.4% during the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock worth $314,849,000 after purchasing an additional 634,099 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Dianthus Therapeutics by 160.9% during the third quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company's stock worth $64,474,000 after purchasing an additional 451,597 shares during the period. Jennison Associates LLC acquired a new position in shares of Dianthus Therapeutics during the first quarter worth approximately $40,713,000. Finally, Pictet Asset Management Holding SA lifted its holdings in shares of Dianthus Therapeutics by 86.9% in the 3rd quarter. Pictet Asset Management Holding SA now owns 462,290 shares of the company's stock worth $40,705,000 after purchasing an additional 214,995 shares in the last quarter. Institutional investors own 47.53% of the company's stock.

Insider Activity at Dianthus Therapeutics

In related news, Director Simon Read sold 2,778 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director directly owned 2,778 shares of the company's stock, valued at approximately $326,553.90. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Edward Carr sold 20,000 shares of the firm's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the transaction, the chief accounting officer owned 20,000 shares in the company, valued at approximately $2,027,600. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 45,902 shares of company stock valued at $4,814,779. 3.02% of the stock is owned by insiders.

Analyst Ratings Changes

DNTH has been the subject of several research reports. Roth Capital initiated coverage on shares of Dianthus Therapeutics in a research report on Tuesday, October 27th. They issued a "buy" rating and a $113.00 price target for the company. Citigroup initiated coverage on shares of Dianthus Therapeutics in a report on Friday, September 4th. They set a "buy" rating and a $156.00 price objective on the stock. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, September 11th. They issued an "overweight" rating and a $135.00 price objective on the stock. Finally, Raymond James Financial reiterated a "strong-buy" rating and set a $134.00 price objective on shares of Dianthus Therapeutics in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of "Buy" and a consensus target price of $128.77.

Dianthus Therapeutics Stock Up 4.6%

Shares of Dianthus Therapeutics stock opened at $90.00 on Tuesday. The company has a market cap of $4.93 billion, a PE ratio of -22.56 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88. The business has a 50 day moving average price of $89.73 and a 200-day moving average price of $85.78.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 21.15% and a negative net margin of 7,436.50%. The company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.60 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.